AVDL AVADEL PHARMACEUTICALS PLC Product Launches 8-K Filing 2024 - FDA Approval Avadel Pharmaceuticals announced FDA approval for LUMRYZ, a treatment for cataplexy and excessive daytime sleepiness in children with narcolepsy, along with Orphan Drug Exclusivity for seven years until October 16, 2031.Get access to all SEC 8-K filings of the AVADEL PHARMACEUTICALS PLC